A322970 Stock Overview
Develops gene therapies based on its proprietary gene-editing platform technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Moogene Medi Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,355.00 |
| 52 Week High | ₩3,385.00 |
| 52 Week Low | ₩1,350.00 |
| Beta | 0 |
| 1 Month Change | -5.23% |
| 3 Month Change | 30.83% |
| 1 Year Change | -16.78% |
| 3 Year Change | -48.80% |
| 5 Year Change | n/a |
| Change since IPO | -60.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| A322970 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.5% | 0.1% | -1.6% |
| 1Y | -16.8% | 16.9% | -9.1% |
Return vs Industry: A322970 underperformed the KR Biotechs industry which returned 16.9% over the past year.
Return vs Market: A322970 underperformed the KR Market which returned -9.1% over the past year.
Price Volatility
| A322970 volatility | |
|---|---|
| A322970 Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A322970's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A322970's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | www.moogene.com |
Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology. The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus. Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease.
Moogene Medi Co., Ltd. Fundamentals Summary
| A322970 fundamental statistics | |
|---|---|
| Market cap | ₩23.04b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A322970 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A322970 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A322970 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 16:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Moogene Medi Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|